José A García-Sáenz

Summary

Publications

  1. pmc Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
    Thomas Bachelot
    EORTC, Soft Tissue and Bone Sarcoma Group, Centre Léon Bérard and Université Claude Bernard, Lyon, France
    BMC Cancer 14:166. 2014
  2. ncbi Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:737-47. 2009
  3. ncbi Circulating tumour cells in locally advanced breast cancer
    Jose Angel Garcia-Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:544-7. 2009
  4. ncbi Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid
    Jose Angel Garcia Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Med Oral Patol Oral Cir Bucal 12:E351-6. 2007
  5. ncbi Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients
    Jose Angel Garcia-Saenz
    Servicio de Oncología Médica Hospital Universitario San Carlos Madrid Spain
    Clin Transl Oncol 8:826-9. 2006
  6. ncbi Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma
    José A García-Sáenz
    Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:676-80. 2006
  7. ncbi Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Breast Cancer 6:325-9. 2005
  8. ncbi Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
    José A García-Sáenz
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 13:121-32. 2011
  9. ncbi Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies
    Javier Puente Vázquez
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:50-3. 2006
  10. ncbi Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
    Carlos Jara-Sánchez
    Unidad de Oncología Médica, Fundacion Hospital Alcorcon, Madrid, Spain
    Clin Breast Cancer 3:399-404. 2003

Collaborators

Detail Information

Publications10

  1. pmc Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study
    Thomas Bachelot
    EORTC, Soft Tissue and Bone Sarcoma Group, Centre Léon Bérard and Université Claude Bernard, Lyon, France
    BMC Cancer 14:166. 2014
    ..This phase II study evaluated the efficacy and safety/tolerability of sunitinib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC)...
  2. ncbi Biomarkers and anti-EGFR therapies for KRAS wild-type metastatic colorectal cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:737-47. 2009
    ..Such patterns may be a novel and cost-effective tool to develop tailored treatments. This manuscript will review biomarkers and molecular pathways that are involved in the tumour response to anti-EGFR therapies...
  3. ncbi Circulating tumour cells in locally advanced breast cancer
    Jose Angel Garcia-Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Clin Transl Oncol 11:544-7. 2009
    ..Two blood samples were obtained from 72 eligible LABC patients to isolate and enumerate CTCs before neoadjuvant chemotherapy started on day 1, and on day 21, immediately before second cycle administration...
  4. ncbi Osteonecrosis of the jaw as an adverse bisphosphonate event: three cases of bone metastatic prostate cancer patients treated with zoledronic acid
    Jose Angel Garcia Saenz
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Madrid, Spain
    Med Oral Patol Oral Cir Bucal 12:E351-6. 2007
    ..Here we report our findings on all 2005 OJN cases presented at our institution resulting from bone metastatic prostate cancer treated with zoledronic acid. The incidence of ONJ is nearly 3% (3 out of 104) in these patients...
  5. ncbi Circulating tumoral cells lack circadian-rhythm in hospitalized metastasic breast cancer patients
    Jose Angel Garcia-Saenz
    Servicio de Oncología Médica Hospital Universitario San Carlos Madrid Spain
    Clin Transl Oncol 8:826-9. 2006
    ..The relationship between breast cancer and circadian rhythm variation has been extensively studied. Increased breast tumorigenesis has been reported in melatonin-suppressed experimental models and in observational studies...
  6. ncbi Significance of the immunohistochemical detection of lymph node micrometastases in stage II colorectal carcinoma
    José A García-Sáenz
    Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:676-80. 2006
    ..Immunohistochemistry is being explored to detect undetectable microscopic lymph node micrometastases...
  7. ncbi Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer
    José A García-Sáenz
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Breast Cancer 6:325-9. 2005
    ..To determine the activity of successive trastuzumab-containing regimens in HER2-overexpressing metastatic breast cancer (MBC) as well as the response rate (RR), time to progression (TTP), and predictive factors for response...
  8. ncbi Platinum-based adjuvant chemotherapy on moderate- and high-risk stage I and II epithelian ovarian cancer patients. Long-term single institution experience and literature review
    José A García-Sáenz
    Medical Oncology Department, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 13:121-32. 2011
    ..Suboptimal survival results have led to major efforts to identify prognostic factors, improve surgical staging and develop adjuvant therapies to improve patients' outcomes...
  9. ncbi Brain metastases in metastatic breast cancer patients receiving trastuzumab-based therapies
    Javier Puente Vázquez
    Servicio de Oncologia Medica, Hospital Clinico San Carlos, Madrid, Spain
    Clin Transl Oncol 8:50-3. 2006
    ..CNS metastases mean a great challenge. It has been suggested that the brain metastases incidence could be high in metastasic breast cancer patients receiving trastuzumab based-therapies...
  10. ncbi Vinorelbine as a 96-hour continuous infusion in heavily pretreated patients with metastatic breast cancer: a cooperative study by the GEICAM group
    Carlos Jara-Sánchez
    Unidad de Oncología Médica, Fundacion Hospital Alcorcon, Madrid, Spain
    Clin Breast Cancer 3:399-404. 2003
    ..However, the results do not indicate clear advantages compared to the conventional weekly scheme of administration...